BIRC5 and gastric cancer: Their results indicated that nuclear survivin expression above 20% decreased the risk of relapse and death compared to those without expression.[20] Similar findings were observed in a study by Okada et al, which evaluated survivin expression in patients diagnosed with gastric cancer.